Baxter International Inc

For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.

Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

Flows into investment-grade bond funds (LQD) were negative in the week ending June 17. This was the second consecutive week witnessing outflows.

The S&P 500 Index, represented by the SPDR S&P 500 ETF (SPY), rose 0.3% on October 23, nearing the all-time high it saw in July.

On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.

In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.

On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.

Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.

Baxter International’s (BAX) global business units delivered strong performances in the second quarter.

Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018.

Baxter (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt for $185.0 million.

On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.

Baxter International (BAX) has been going through a cost transformation and reorganization process for some time. The initiative includes some leadership and management changes.

On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.

Thermo Fisher Scientific expects to deploy 60%–75% of its capital toward M&As (mergers and acquisitions).

Thermo Fisher Scientific (TMO) has always focused on innovation as a key growth strategy.

Baxter International’s R&D investments were around $150 million in 2Q16, which represents a YoY (year-over-year) increase of around 1%.

Medtronic established a services and solutions growth vector as one of its core strategies. It contributed ~20 basis points to Medtronic’s growth in 3Q16.

On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.

Thermo Fisher Scientific is a global company, but the majority of its revenues are generated from the developed markets. The US is its largest market, generating ~48% of the company’s total revenues.

Thermo Fisher Scientific’s Laboratory Products and Services segment earned revenues of approximately $6.6 billion in 2014, representing organic growth of around 5%.

Becton, Dickinson and Company (BDX), or BD, has operations across the globe, with more than 50% of its 2015 revenues coming from international markets.

Becton, Dickinson and Company, or BD, headquartered in Franklin Lakes, New Jersey, is one of the leading medical technology companies in the United States.

On October 1, 2015, BD underwent organizational restructuring to better align its business model to the strategic vision and goals of the company.

The US medical device market is projected to grow at a compound annual growth rate of 6.1% between 2014 and 2017.

Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline.